Back to Journals Drug Design, Development and Therapy Volume 13 The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date Authors Antza C , Nirantharakumar K , Doundoulakis I, Tahrani AA, Toulis KA Received 31 October 2018 Accepted for publication 27 June 2019 Published 22 August 2019 Volume 2019:13 Pages 29852996 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Tuo Deng Christina Antza, 1,* Krishnarajah Nirantharakumar, 2,* Ioannis Doundoulakis, 3 Abd A Tahrani, 46 Konstantinos A Toulis 2, 3 1 3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece
The statement is notable for characterizing obesity as a chronic, complex disease that requires lifelong care but its recommendations arent without caveats
Each COA documents component identity by HPLC and mass spectrometry, purity per component (typically 99%), and, where applicable, sterility and endotoxin testing, plus lot-specific storage guidance
GHK-Cu: Overview GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptidemetal complex identified in biological fluids and extracellular matrices
